Tetrahydrocurcumin

Tetrahydrocurcumin

SCHEMBL284877

COc1cc(CCC(=O)CC(=O)CCc2ccc(O)c(OC)c2)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 1.00
OR51E2 Q9H255 1/20 1.00
CYP3A4 P08684 4/20 0.70
CYP2C8 P10632 4/20 0.70
CYP2C9 P11712 4/20 0.70
CYP2B6 P20813 4/20 0.70
CYP2C19 P33261 4/20 0.70
CYP1A2 P05177 3/20 0.70
TAAR1 Q96RJ0 2/20 0.63
TSHR P16473 2/20 0.63
MAPK1 P28482 1/20 0.63
TRPV1 Q8NER1 2/20 0.62
LMNA P02545 1/20 0.61
GLA P06280 1/20 0.61
MTNR1A P48039 1/20 0.61
MTNR1B P49286 1/20 0.61
LTA4H P09960 2/20 0.61
GAA P10253 2/20 0.61
POLB P06746 1/20 0.61
HTR1A P08908 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrahydrocurcumin SCHEMBL29370299 1.00 ALOX5 (1.00) ALOX5OR51E2CYP3A4CYP2C8CYP2C9
Tetrahydrocurcumin SCHEMBL29372158 1.00 ALOX5 (1.00) ALOX5OR51E2CYP3A4CYP2C8CYP2C9
SCHEMBL10307533 0.95 ALOX5 (0.91) ALOX5OR51E2CYP3A4CYP2C8CYP2C9
SCHEMBL10307817 0.95 ALOX5 (0.91) ALOX5OR51E2CYP3A4CYP2C8CYP2C9
SCHEMBL645127 0.94 ALOX5 (0.89) ALOX5OR51E2CYP3A4CYP2C8CYP2C9
SCHEMBL10307751 0.94 ALOX5 (0.89) ALOX5OR51E2CYP3A4CYP2C8CYP2C9
Tetrahydrodemethoxycurcumin SCHEMBL29565582 0.94 ALOX5 (0.89) ALOX5OR51E2CYP3A4CYP2C8CYP2C9
Tetrahydrodemethoxycurcumin SCHEMBL4413210 0.94 ALOX5 (0.89) ALOX5OR51E2CYP3A4CYP2C8CYP2C9
SCHEMBL28355932 0.93 ALOX5 (0.88) ALOX5OR51E2CYP3A4CYP2C8CYP2C9
SCHEMBL10307531 0.93 ALOX5 (0.86) ALOX5OR51E2CYP3A4CYP2C8CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118986944-A Application of tetrahydrocurcumin in inhibiting valve mesenchymal cell calcification 重庆医科大学 2024-11-22 CN claimed
US-20210060166-A1 Method for the preparation of a 1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione system in polysorbates for the formation of micelles in an aqueous medium aimed at the properties of the bioavailability of curcuminoids ASTUDILLO DE LA VEGA HORACIO (MX) 2021-03-04 US claimed
US-8119696-B2 Treatment of superficial and cutaneous mycoses with a pure form of 1,7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione Majeed, Muhammed (US) 2012-02-21 US claimed
US-20090318565-A1 Novel Compositions for the Enhancement of the Anti-oxidant Potential of Hydrogenated Curcuminoids or Combinations Thereof MAJEED MUHAMMED 2009-12-24 US claimed
US-20090275665-A1 Enhanced biological potential of greater than 99% pure form of 1, 7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione over corresponding 95% pure form-therapeutic and agricultural applications thereof SAMI LABS LIMITED (IN) 2009-11-05 US claimed
US-6875426-B2 Self-tanning composition containing a tetrahydrocurcuminoid and a self-tanning agent L'OREAL (FR) 2005-04-05 US claimed
US-6872401-B2 Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil L'OREAL (FR) 2005-03-29 US claimed
US-20040009200-A1 Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil SOCIETE L'OREAL S.A. (FR) 2004-01-15 US claimed
US-20030228268-A1 Self-tanning composition containing a tetrahydrocurcuminoid and a self-tanning agent SOCIETE L'OREAL S.A. (FR) 2003-12-11 US claimed
EP-1348418-A1 Cosmetical or dermatological composition containing a tetrahydrocurcumin derivative and an oil bearing an amide group L'OREAL (FR) 2003-10-01 EP claimed
EP-1348424-A1 Self-tanning composition containing a tetrahydrocurcumine derivative and a self-tanning agent L'OREAL (FR) 2003-10-01 EP claimed
US-20250255853-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2025-08-14 US disclosed
US-12303470-B2 Method and composition for selective treatment of androgen receptors SKINQRI, LLC (US) 2025-05-20 US disclosed
US-12186294-B2 Modulators of prostate-specific g-protein receptor (PSGR/OR51E2) and methods of using same DUKE UNIVERSITY (US) 2025-01-07 US disclosed
CN-118986944-A Application of tetrahydrocurcumin in inhibiting valve mesenchymal cell calcification 重庆医科大学 2024-11-22 CN disclosed
US-5208251-A Compounds for antiinflammatory agents, antiallergens, antiarthritic, antiulcer agents WARNER-LAMBERT COMPANY (US) 1993-05-04 US disclosed
EP-0245825-B1 STYRYL PYRAZOLES, ISOXAZOLES AND ANALOGS THEREOF HAVING ACTIVITY AS 5-LIPOXY-GENASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM WARNER-LAMBERT COMPANY (US) 1991-03-13 EP disclosed
US-4924002-A REACTION WITH MOLYBDENUM CARBONYL AND HYDRAZINE WARNER-LAMBERT COMPANY (US) 1990-05-08 US disclosed
US-4877881-A SUNSCREEN WARNER-LAMBERT COMPANY (US) 1989-10-31 US disclosed
EP-0245825-A1 Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them WARNER-LAMBERT COMPANY (US) 1987-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275665-A1 Enhanced biological potential of greater than 99% pure form of 1, 7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione over corresponding 95% pure form-therapeutic and agricultural applications thereof CYP8B1, HPD, HAAO ALOX5 268/4885OR51E2 906/4885CYP3A4 94/4885
US-12303470-B2 Method and composition for selective treatment of androgen receptors AR, ARNT, SHBG ALOX5 726/4885OR51E2 801/4885CYP3A4 1388/4885
US-20030228268-A1 Self-tanning composition containing a tetrahydrocurcuminoid and a self-tanning agent TYR, TES, TERT ALOX5 963/4885OR51E2 3141/4885CYP3A4 1628/4885
US-20090318565-A1 Novel Compositions for the Enhancement of the Anti-oxidant Potential of Hydrogenated Curcuminoids or Combinations Thereof GPX4, HMOX1, GPX1 ALOX5 36/4885OR51E2 1306/4885CYP3A4 460/4885
US-20040009200-A1 Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil KRT18, DHCR24, FABP4 ALOX5 39/4885OR51E2 3668/4885CYP3A4 1221/4885
US-20250255853-A1 HUMAN THERAPEUTIC AGENTS HASPIN, TIPARP, SHARPIN ALOX5 2214/4885OR51E2 4014/4885CYP3A4 3496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.